Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: Results of a phase II study of the GIMEMA CML Working Party

Haematologica

Volumn 92, Issue 1, 2007, Pages 101-105

  Rosti, Gianantonio ^a   Iacobucci, Ilaria ^a   Bassi, Simona ^b   Castagnetti, Fausto ^a   Amabile, Marilina ^a   Cilloni, Daniela ^c   Poerio, Angela ^a   Soverini, Simona ^a   Palandri, Francesca ^a   Cambrin, Giovanna Rege ^c   Iuliano, Franco ^d   Alimena, Giuliana ^e   Latagliata, Roberto ^f   Testoni, Nicoletta ^a   Pane, Fabrizio ^a,f   Saglio, Giuseppe ^c   Baccarani, Michele ^a   Martinelli, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d PUGLIESE CIACCIO HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chronic myeloid leukemia; Imatinib; Older age

Indexed keywords

IMATINIB; INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 33846935242     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10239     Document Type: Article

References (22)

1. Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985;66:1366-35.
2. Kantarjian H, Keating M, McCredie K. Old age is a sign of poor prognosis in patients with chronic myelogenous leukemia. Southern Med J 1988;80:1233-35.
3. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian, HM. The biology of chronic myeloid leukaemia. N Engl J Med 1999;341: 164-72.
4. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996;100:452-5.
5. Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, et al. Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. Leuk Res 1998;22:881-6.
6. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. The Leukemia Service. Ann Intern Med 1995; 122:254-61.
7. Shepherd PC, Richards SM, Allan NC.Progress with interferon in CML - results of the MRC UK CML III study. Bone Marrow Transplant 1996;17Suppl 3:S15-8.
8. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
9. Kantarjian HM, Sawyers CL, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to Imatinib mesylate in chronic myelogenous leukemia. International STI571 CML Study Group. N Engl J Med 2002;346:645-52.
10. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928-37.
11. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99:3547-53.
12. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood 2004;104:4245-51.
13. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965-71.
14. Sureda A, Carrasco M, de Miguel M, Martinez JA, Conde E, Sanz MA, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003;88:1213-20.
15. Cervantes F, Hernandez-Boluda JC, Steegmann JL, Conde E, Alvarez-Larran A, Lopez-Jimenez J, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003;88:1117-22.
16. Colombat M, Fort MP, Chollet C, Marit G, Roche C, Preudhomme C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica 2006;91:162-8.
17. Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon /araC. Leukemia 2003; 17:2392-00.
18. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003;98:1105-13.
19. Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, et al. Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia. Blood 2004;103:2284-90.
20. + chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 2006;24:454-9.
21. Martinelli G, Iacobucci I, Rosti G, Pane F, Amabile M, Castagnetti F, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol 2006;17:495-502.
22. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 1990;88:1-8.